Skip to search formSkip to main contentSkip to account menu

netupitant

Known as: 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide, 2-[3,5-bis(Trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide 
A selective neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity. Netupitant competitively binds to and blocks the activity of… 
National Institutes of Health

Related topics

Related topics

5 relations
Breast Cancer Resistance Protein Inhibitors [MoA]aprepitantnetupitant / palonosetronnetupitant 300 MG / palonosetron 0.5 MG Oral Capsule [Akynzeo]

Broader (1)

Pyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated…
2019
2019
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients
PurposeChemotherapy-induced nausea and vomiting (CINV) is one of the most feared and disturbing adverse events of cancer… 
Review
2017
Review
2017
Ca2+ signaling and emesis: Recent progress and new perspectives
2016
2016
Accelerated onset of the vesicovesical reflex in postnatal NGF-OE mice and the role of neuropeptides
Review
2016
Review
2016
The role of netupitant and palonosetron in chemotherapy-induced nausea and vomiting
The combination of netupitant and palonosetron was approved by the Food and Drug Administration in October 2014 for the… 
2015
2015
Rolapitant for the treatment of chemotherapy-induced nausea and vomiting
Chemotherapy-induced nausea and vomiting is a significant clinical issue which affects patient’s quality of life and treatment… 
2014
2014
Netupitant-palonosetron combination approved by FDA.
FDA on October 10 approved the marketing of netupitant–palonosetron capsules for the prevention of nausea and vomiting related to… 
2013
2013
Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately…
LBA9514 Background: Management of CINV has been refined over the past several decades and CINV can now be managed with targeted… 
2013
2013
No Evidence Of Increased Cyclophosphamide Toxicity Associated With The Antiemetic Agent NEPA, a Fixed-Dose Combination Of Netupitant and Palonosetron
Background Cyclophosphamide (CTX), a commonly used alkylating agent in the treatment of hematological malignancies and solid… 
2012
2012
A positron emission tomography (PET) study to assess the degree of neurokinin-1 (NK1) receptor occupancy in the human brain after single doses of netupitant to healthy male subjects.
9054 Background: Netupitant (NETU) is a highly selective neurokinin 1 (NK1) receptor antagonist for the prevention of nausea and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)